Detalhe da pesquisa
1.
Molecular, clinical and therapeutic determinants of outcome in NPM1 mutated AML.
Blood
; 2024 May 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38691678
2.
Therapy for isocitrate dehydrogenase 2 (IDH2)R172 -mutant acute myeloid leukaemia.
Br J Haematol
; 196(6): 1348-1352, 2022 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-34870324
3.
Genomic landscape and clonal evolution of acute myeloid leukemia with t(8;21): an international study on 331 patients.
Blood
; 133(10): 1140-1151, 2019 03 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-30610028
4.
Analysis of the clinical impact of NPM1 mutant allele burden in a large cohort of younger adult patients with acute myeloid leukaemia.
Br J Haematol
; 188(6): 852-859, 2020 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-31595497
5.
Assessment of Minimal Residual Disease in Standard-Risk AML.
N Engl J Med
; 374(5): 422-33, 2016 Feb 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-26789727
6.
A randomized assessment of adding the kinase inhibitor lestaurtinib to first-line chemotherapy for FLT3-mutated AML.
Blood
; 129(9): 1143-1154, 2017 03 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-27872058
7.
Activation of the LMO2 oncogene through a somatically acquired neomorphic promoter in T-cell acute lymphoblastic leukemia.
Blood
; 129(24): 3221-3226, 2017 06 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-28270453
8.
Immunophenotypic analysis of cell cycle status in acute myeloid leukaemia: relationship to cytogenetics, genotype and clinical outcome.
Br J Haematol
; 181(4): 486-494, 2018 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-29676467
9.
Variable outcome and methylation status according to CEBPA mutant type in double-mutated acute myeloid leukemia patients and the possible implications for treatment.
Haematologica
; 103(1): 91-100, 2018 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29025912
10.
Detection of FLT3/TKD and IDH1 Mutations in Pakistani Acute Myeloid Leukemia Patients by Denaturing HPLC.
J Cell Biochem
; 118(5): 1174-1181, 2017 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-27735988
11.
Downregulation of the Wnt inhibitor CXXC5 predicts a better prognosis in acute myeloid leukemia.
Blood
; 125(19): 2985-94, 2015 May 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-25805812
12.
The value of molecular stratification for CEBPA(DM) and NPM1(MUT) FLT3(WT) genotypes in older patients with acute myeloid leukaemia.
Br J Haematol
; 172(4): 573-80, 2016 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-26847745
13.
Cell cycle status in AML blast cells from peripheral blood, bone marrow aspirates and trephines and implications for biological studies and treatment.
Br J Haematol
; 174(2): 275-9, 2016 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-27061724
14.
X chromosome inactivation analysis reveals a difference in the biology of ET patients with JAK2 and CALR mutations.
Blood
; 124(13): 2091-3, 2014 Sep 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-25139350
15.
Impact of FLT3(ITD) mutant allele level on relapse risk in intermediate-risk acute myeloid leukemia.
Blood
; 124(2): 273-6, 2014 Jul 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-24855211
16.
The clinical impact of mutant DNMT3A R882 variant allele frequency in acute myeloid leukaemia.
Br J Haematol
; 189(3): e81-e86, 2020 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-32004382
17.
In trans early mosaic mutational escape and novel phenotypic features of germline SAMD9 mutation.
Br J Haematol
; 188(4): e53-e57, 2020 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-31900929
18.
No evidence that CD33 splicing SNP impacts the response to GO in younger adults with AML treated on UK MRC/NCRI trials.
Blood
; 131(4): 468-471, 2018 01 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-29229596
19.
Impact of isolated germline JAK2V617I mutation on human hematopoiesis.
Blood
; 121(20): 4156-65, 2013 May 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-23535062
20.
PIM and AKT kinase inhibitors show synergistic cytotoxicity in acute myeloid leukaemia that is associated with convergence on mTOR and MCL1 pathways.
Br J Haematol
; 167(1): 69-79, 2014 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-24975213